Trial Profile
A Multicenter, Multinational, Prospective, Interventional, Single-arm, Phase IV Study Evaluating the Clinical Efficacy and Safety of 26 Weeks of Treatment With Insulin Glargine 300 U/mL (Gla-300) in Patients With Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jun 2022
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ARTEMIS-DM
- Sponsors Sanofi
- 17 Jun 2022 Results published in the Diabetes Therapy
- 07 Jun 2022 Results presented at the 82nd Annual Scientific Sessions of the American Diabetes Association
- 29 Sep 2020 Status changed from active, no longer recruiting to completed.